

IN THE CLAIMS

Please amend the claims as follows:

Please amend the claims as follows:

1. (Currently Amended) A method of treating traumatic brain injury in a mammal suffering from traumatic brain injury, comprising administering to the mammal suffering from traumatic brain injury, human G-CSF, or a protein having at least 90% homology to ~~SEQ ID NO:28~~ ~~SEQ ID NO:38~~ and G-CSF activity, in an amount sufficient to treat the traumatic brain injury; and assessing neurological function in the mammal after said administering.
2. (Cancelled).
3. (Cancelled).
4. (Cancelled).
5. (Cancelled).
6. (Cancelled).
7. (Cancelled).
8. (Cancelled).
9. (Previously Presented) The method of Claim 1, wherein human G-CSF is administered.
10. (Cancelled).
11. (Cancelled).
12. (Cancelled).
13. (Cancelled).
14. (Cancelled).
15. (Cancelled).

16. (Cancelled).

17. (Cancelled).

18. (Previously Presented) The method of Claim 1, wherein the mammal treated is human.

19. (Currently Amended) The method of Claim 1, wherein the human G-CSF, or a protein having at least 90% homology to SEQ ID NO:38 ~~SEQ ID NO:28 and G-CSF activity~~ is administered by one or more modes of administration selected from the group consisting of direct intracerebral injection, intravenously, intraarterially, orally, and ~~subcutaneously~~ subcutaneously.

Claims 20-104 (Cancelled).

105.(Currently Amended) A method of treating traumatic brain injury in a mammal suffering from traumatic brain injury, comprising intravenously administering to the mammal suffering from traumatic brain injury, human G-CSF, or a protein having at least 90% homology to SEQ ID NO:38 ~~SEQ ID NO:28 and G-CSF activity~~ in an amount sufficient to treat the traumatic brain injury; and

assessing neurological function in the mammal after said administering.

106. (Previously Presented) The method of Claim 105, comprising intravenously administering human G-CSF.

107.(Currently Amended) The method of Claim 105, comprising intravenously administering a protein having at least 90% homology to SEQ ID NO:38 ~~SEQ ID NO:28 and G-CSF activity~~.

108.(Currently Amended) The method of Claim 105, comprising intravenously administering a protein having at least 95% homology to SEQ ID NO:38SEQ ID NO:28 and G-CSF activity.

109.(Cancelled).

110.(Cancelled).

111.(Cancelled).

112.(Cancelled).

113.(Cancelled).

114.(New) The method of Claim 1, wherein human G-CSF has the amino acid sequence in SEQ ID NO:37, SEQ ID NO:38, or SEQ ID NO:39.

115.(New) The method of Claim 105, wherein human G-CSF has the amino acid sequence in SEQ ID NO:37, SEQ ID NO:38, or SEQ ID NO:39.

116. (New) The method of Claim 114, wherein human G-CSF has the amino acid sequence in SEQ ID NO:38.

117.(New) The method of Claim 115, wherein human G-CSF has the amino acid sequence in SEQ ID NO:38.